As Alligator Bioscience makes headways with its clinical development of cancer immunotherapy mitazalimab, the company’s bispecific antibody technology RUBY is also turning heads. Alligator has announced extending its collaboration with Orion Corporation for the discovery of a second novel bispecific antibody directed towards immuno-oncology targets. BioStock spoke with Alligator’s CEO Søren Bregenholt to learn more.
Read the interview with Søren Bregenholt at biostock.se:
Alligator Bioscience extends collaboration with Orion Corporation – BioStock
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/